Concepts (126)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 20 | 2025 | 1350 | 5.820 |
Why?
|
| Community Health Workers | 6 | 2025 | 72 | 3.160 |
Why?
|
| Telemedicine | 7 | 2025 | 488 | 3.010 |
Why?
|
| Hypoglycemic Agents | 7 | 2025 | 456 | 2.350 |
Why?
|
| Diabetes Mellitus | 7 | 2025 | 873 | 2.220 |
Why?
|
| Cardiovascular Diseases | 11 | 2025 | 2036 | 0.940 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2025 | 32 | 0.940 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2025 | 480 | 0.810 |
Why?
|
| Metformin | 3 | 2024 | 159 | 0.800 |
Why?
|
| Self-Management | 1 | 2024 | 110 | 0.760 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2025 | 267 | 0.740 |
Why?
|
| Poverty | 5 | 2025 | 431 | 0.710 |
Why?
|
| Patient Education as Topic | 1 | 2024 | 452 | 0.680 |
Why?
|
| Diabetic Foot | 1 | 2022 | 165 | 0.630 |
Why?
|
| Patient Selection | 1 | 2023 | 711 | 0.630 |
Why?
|
| House Calls | 1 | 2019 | 36 | 0.580 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2020 | 142 | 0.580 |
Why?
|
| Medically Underserved Area | 1 | 2019 | 87 | 0.560 |
Why?
|
| Humans | 41 | 2025 | 126673 | 0.530 |
Why?
|
| Psychotherapy, Group | 1 | 2017 | 57 | 0.530 |
Why?
|
| Veterans | 3 | 2022 | 1741 | 0.500 |
Why?
|
| Adult | 13 | 2025 | 30377 | 0.450 |
Why?
|
| Patient Care Team | 1 | 2017 | 550 | 0.400 |
Why?
|
| Breast Neoplasms | 1 | 2025 | 2581 | 0.390 |
Why?
|
| Middle Aged | 12 | 2025 | 27671 | 0.390 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2019 | 880 | 0.380 |
Why?
|
| Aged | 10 | 2025 | 20321 | 0.370 |
Why?
|
| Sulfonylurea Compounds | 2 | 2024 | 19 | 0.370 |
Why?
|
| Cardiology | 4 | 2024 | 486 | 0.360 |
Why?
|
| Thiazolidinediones | 2 | 2024 | 79 | 0.360 |
Why?
|
| Female | 15 | 2025 | 68270 | 0.290 |
Why?
|
| Quality of Life | 4 | 2024 | 2027 | 0.280 |
Why?
|
| Male | 14 | 2025 | 62489 | 0.260 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2023 | 734 | 0.240 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2025 | 46 | 0.230 |
Why?
|
| Drug Therapy, Combination | 2 | 2020 | 1136 | 0.230 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2024 | 31 | 0.210 |
Why?
|
| Obesity | 4 | 2025 | 2333 | 0.210 |
Why?
|
| Community Health Centers | 1 | 2023 | 37 | 0.210 |
Why?
|
| Primary Prevention | 1 | 2024 | 172 | 0.200 |
Why?
|
| Depression | 2 | 2023 | 1293 | 0.190 |
Why?
|
| Feedback | 1 | 2023 | 148 | 0.190 |
Why?
|
| Publishing | 1 | 2024 | 100 | 0.190 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2025 | 1184 | 0.190 |
Why?
|
| Health Education | 1 | 2024 | 222 | 0.180 |
Why?
|
| Patient Satisfaction | 1 | 2025 | 456 | 0.180 |
Why?
|
| Research Design | 2 | 2023 | 691 | 0.180 |
Why?
|
| Rural Population | 1 | 2023 | 246 | 0.180 |
Why?
|
| Pediatric Obesity | 2 | 2017 | 408 | 0.170 |
Why?
|
| Social Support | 1 | 2023 | 368 | 0.170 |
Why?
|
| Anticholesteremic Agents | 1 | 2023 | 239 | 0.170 |
Why?
|
| Sleep Wake Disorders | 1 | 2023 | 189 | 0.170 |
Why?
|
| Lower Extremity | 1 | 2022 | 180 | 0.170 |
Why?
|
| Multimorbidity | 1 | 2020 | 25 | 0.160 |
Why?
|
| Goals | 1 | 2021 | 122 | 0.160 |
Why?
|
| Health Status Indicators | 1 | 2020 | 122 | 0.160 |
Why?
|
| Insulins | 1 | 2020 | 18 | 0.160 |
Why?
|
| Mentors | 1 | 2021 | 154 | 0.160 |
Why?
|
| Weight Reduction Programs | 1 | 2020 | 58 | 0.160 |
Why?
|
| Congresses as Topic | 3 | 2025 | 175 | 0.150 |
Why?
|
| Videoconferencing | 1 | 2019 | 21 | 0.150 |
Why?
|
| Aged, 80 and over | 3 | 2025 | 6663 | 0.150 |
Why?
|
| Telephone | 1 | 2019 | 112 | 0.150 |
Why?
|
| Medicaid | 1 | 2021 | 241 | 0.150 |
Why?
|
| Group Processes | 1 | 2019 | 47 | 0.150 |
Why?
|
| Behavior Therapy | 1 | 2021 | 263 | 0.140 |
Why?
|
| Treatment Failure | 1 | 2019 | 334 | 0.140 |
Why?
|
| Diabetes Complications | 1 | 2019 | 194 | 0.140 |
Why?
|
| Treatment Outcome | 3 | 2025 | 12537 | 0.140 |
Why?
|
| Cost of Illness | 1 | 2020 | 282 | 0.140 |
Why?
|
| Administration, Oral | 1 | 2020 | 669 | 0.140 |
Why?
|
| Body Mass Index | 3 | 2020 | 1654 | 0.130 |
Why?
|
| Life Style | 4 | 2021 | 434 | 0.130 |
Why?
|
| Anxiety | 1 | 2023 | 964 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2021 | 1398 | 0.130 |
Why?
|
| Risk Factors | 4 | 2025 | 10545 | 0.130 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2023 | 650 | 0.130 |
Why?
|
| Regression Analysis | 1 | 2017 | 759 | 0.120 |
Why?
|
| Seasons | 1 | 2017 | 309 | 0.120 |
Why?
|
| Weight Loss | 4 | 2021 | 503 | 0.120 |
Why?
|
| Blood Pressure | 1 | 2021 | 1312 | 0.120 |
Why?
|
| Child Behavior | 1 | 2017 | 233 | 0.120 |
Why?
|
| Acculturation | 1 | 2015 | 61 | 0.120 |
Why?
|
| Body Weight | 2 | 2017 | 970 | 0.110 |
Why?
|
| Feasibility Studies | 1 | 2017 | 792 | 0.110 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 658 | 0.110 |
Why?
|
| Blood Glucose | 1 | 2019 | 1082 | 0.110 |
Why?
|
| Pandemics | 1 | 2022 | 1133 | 0.110 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1374 | 0.110 |
Why?
|
| Atherosclerosis | 1 | 2022 | 929 | 0.110 |
Why?
|
| Cohort Studies | 1 | 2023 | 4953 | 0.110 |
Why?
|
| Young Adult | 2 | 2025 | 9655 | 0.110 |
Why?
|
| Retrospective Studies | 2 | 2025 | 16985 | 0.110 |
Why?
|
| Follow-Up Studies | 1 | 2022 | 5112 | 0.100 |
Why?
|
| Overweight | 3 | 2021 | 370 | 0.090 |
Why?
|
| United States | 5 | 2025 | 11297 | 0.090 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 3901 | 0.080 |
Why?
|
| Texas | 1 | 2019 | 3545 | 0.080 |
Why?
|
| Global Health | 2 | 2025 | 608 | 0.080 |
Why?
|
| Kenya | 1 | 2023 | 58 | 0.050 |
Why?
|
| Minimal Clinically Important Difference | 1 | 2023 | 8 | 0.050 |
Why?
|
| Europe | 1 | 2024 | 358 | 0.050 |
Why?
|
| Editorial Policies | 1 | 2024 | 48 | 0.050 |
Why?
|
| Writing | 1 | 2024 | 60 | 0.050 |
Why?
|
| Proprotein Convertase 9 | 1 | 2023 | 108 | 0.050 |
Why?
|
| American Heart Association | 1 | 2025 | 307 | 0.050 |
Why?
|
| Exercise | 2 | 2020 | 839 | 0.050 |
Why?
|
| Residence Characteristics | 1 | 2025 | 271 | 0.050 |
Why?
|
| Data Collection | 1 | 2023 | 369 | 0.050 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2022 | 74 | 0.040 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2021 | 50 | 0.040 |
Why?
|
| Cardiotonic Agents | 1 | 2022 | 135 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2024 | 738 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2023 | 604 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2023 | 258 | 0.040 |
Why?
|
| Diet, Reducing | 1 | 2020 | 88 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 300 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2023 | 1424 | 0.040 |
Why?
|
| Caloric Restriction | 1 | 2020 | 98 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2021 | 330 | 0.030 |
Why?
|
| Glucose | 1 | 2022 | 839 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2017 | 165 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 1194 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2019 | 771 | 0.020 |
Why?
|
| Child | 2 | 2017 | 25081 | 0.020 |
Why?
|
| Adolescent | 1 | 2023 | 19987 | 0.010 |
Why?
|